Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Prior treatment

• Clinically significant cardiovascular disease and prior exposure to cardiotoxic agents.
• Prior treatment with TEAD inhibitor.

Other illness

• History of leptomeningeal metastases
• Active or chronic, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
• Known HIV positive or active Hepatitis B or Hepatitis C
• Additional active malignancy that may confound the assessment of the study endpoints

Lab values

• Corrected QT (QTcF) interval \> 470 msec (using Fridericia's correction formula).

Other

• Active brain metastases or primary CNS (central nervous system) tumors.
• Women who are pregnant or breastfeeding

• Part 3 Combination Cohort A: Patients with pathologically diagnosed, metastatic or unresectable malignant mesothelioma (including both pleural and non-pleural) who have not received systemic therapy.
• Part 3 Combination Cohort B: Patients with pathologically diagnosed incurable locally advanced (inoperable or recurrent), or metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations, with or without prior treatment with Osimertinib.
• Part 3 Combination Cohort C: Patients with pathologically diagnosed metastatic or unresectable malignant pleural mesothelioma who have not received systemic chemotherapy.
• Measurable disease per RECIST v1.1 for non-pleural mesothelioma or other solid tumors or modified RECIST v1.1 for malignant pleural mesothelioma. mRECIST may be used for pleural extension of non-pleural mesothelioma or for mixed pleural and peritoneal (or other) mesothelioma.
• ECOG: 0-1.
• Adequate organ functions, including the liver, kidneys, and hematopoietic system.